Kumar Rahul, Nolan Kevin, Kassa Biruk, Chanana Neha, Palmo Tsering, Sharma Kavita, Singh Kanika, Mickael Claudia, Fonseca Balladares Dara, Nilsson Julia, Prabhakar Amit, Mishra Aastha, Lee Michael H, Sanders Linda, Kumar Sushil, Molofsky Ari B, Stenmark Kurt R, Sheppard Dean, Tuder Rubin M, Gupta Mohit D, Thinlas Tashi, Pasha Qadar, Graham Brian B
Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Lung Biology Center, Zuckerberg San Francisco General Hospital, San Francisco, California, USA.
J Clin Invest. 2025 Jan 30;135(6):e176865. doi: 10.1172/JCI176865.
Hypoxia is a major cause of pulmonary hypertension (PH) worldwide, and it is likely that interstitial pulmonary macrophages contribute to this vascular pathology. We observed in hypoxia-exposed mice an increase in resident interstitial macrophages, which expanded through proliferation and expressed the monocyte recruitment ligand CCL2. We also observed an increase in CCR2+ macrophages through recruitment, which express the protein thrombospondin-1, which functionally activates TGF-β to cause vascular disease. Blockade of monocyte recruitment with either CCL2-neutralizing antibody treatment or CCR2 deficiency in the bone marrow compartment suppressed hypoxic PH. These data were supported by analysis of plasma samples from humans who traveled from low (225 m) to high (3500 m) elevation, revealing an increase in thrombospondin-1 and TGF-β expression following ascent, which was blocked by dexamethasone prophylaxis. In the hypoxic mouse model, dexamethasone prophylaxis recapitulated these findings by mechanistically suppressing CCL2 expression and CCR2+ monocyte recruitment. These data suggest a pathologic cross talk between 2 discrete interstitial macrophage populations, which can be therapeutically targeted.
低氧是全球范围内肺动脉高压(PH)的主要病因,肺间质巨噬细胞很可能参与了这一血管病变过程。我们在低氧暴露的小鼠中观察到,驻留的肺间质巨噬细胞数量增加,这些细胞通过增殖而扩张,并表达单核细胞募集配体CCL2。我们还观察到通过募集,CCR2+巨噬细胞数量增加,这些细胞表达血小板反应蛋白-1,该蛋白可功能性激活转化生长因子-β(TGF-β)从而导致血管疾病。用CCL2中和抗体治疗或骨髓区室中CCR2缺陷来阻断单核细胞募集,可抑制低氧性肺动脉高压。对从低海拔(225米)前往高海拔(3500米)的人群的血浆样本分析支持了这些数据,结果显示海拔上升后血小板反应蛋白-1和TGF-β表达增加,而地塞米松预防可阻断这一增加。在低氧小鼠模型中,地塞米松预防通过机制性抑制CCL2表达和CCR2+单核细胞募集重现了这些发现。这些数据表明,两种不同的肺间质巨噬细胞群体之间存在病理性相互作用,这一相互作用可成为治疗靶点。